US FDA
Fayetteville VA Medical Center
2026-09-03
Fairlue to appropriately and regularly clean and disinfect or sterilize equipment located in the ISO 5 area.
View official sourceBy Country
United States manufacturing-site findings
at manufacturing sites in this country 8,304 findings drawn from 1,342 published documents. The most recent cases are below; the full set is in search.
See all United States findingsWhich agency cited it
US FDA
8,302
EMA (Europe)
2
Companies with the most findings
Recent findings
US FDA
Fayetteville VA Medical Center
2026-09-03
Beta-lactam drugs were produced without providing adequate containment, segregation, and/or cleaning of work surfaces, utensils, and/or personnel to prevent cross-contamination.
View official source
US FDA
Fayetteville VA Medical Center
2026-09-03
Microbial contamination was present in the.
View official source
US FDA
Veterinary Pharmacy Corporation
2026-08-12
Deviation from the procedural requirements of a decree of injunction.
See every finding in this document View official source
US FDA
Veterinary Pharmacy Corporation
2026-08-12
Failure to conduct media fills that closely simulate aseptic production operations under the worst-case, most-challenging, and stressful conditions.
See every finding in this document View official source
US FDA
Veterinary Pharmacy Corporation
2026-08-12
Contamination was observed in your production area and areas adjacent to production areas.
See every finding in this document View official sourceOther countries
These findings are a record of the moment each document was published. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out — do not read them as the current state; check the regulator's official announcements for the latest status. Counts are measured from public data as of 2026-09-04, and findings are extracted automatically from the regulator's published documents. “View official source” on each case links directly to that document.
